SCHEMBL107964

SCHEMBL107964

O=C(O)c1cccc(F)n1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.70
ALOX15 P16050 1/20 0.70
TSHR P16473 1/20 0.70
ACMSD Q8TDX5 1/20 0.70
TDP1 Q9NUW8 1/20 0.70
LMNA P02545 3/20 0.48
GNE Q9Y223 1/20 0.47
KMT2A Q03164 2/20 0.46
MGAM O43451 1/20 0.45
NAPRT Q6XQN6 1/20 0.45
P4HTM Q9NXG6 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ECE1 P42892 1/20 0.43
GRM4 Q14833 3/20 0.43
CTSA P10619 2/20 0.42
MEN1 O00255 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29723811 1.00 KDM4E (0.70) KDM4EALOX15TSHRACMSDTDP1
Hydrochloric Acid SCHEMBL11682457 0.98 KDM4E (0.67) KDM4EALOX15TSHRACMSDTDP1
Acetic Acid Methyl Ester SCHEMBL28398490 0.87 KDM4E (0.53) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL3552924 0.84 KDM4E (0.46) KDM4EALOX15TSHRACMSDTDP1
Dipicolinic Acid SCHEMBL720696 0.83 KDM4E (1.00) KDM4EALOX15TSHRACMSDTDP1
Dipicolinic Acid SCHEMBL34595 0.83 KDM4E (1.00) KDM4EALOX15TSHRACMSDTDP1
Imidazole SCHEMBL3837583 0.82 KDM4E (0.47) KDM4EALOX15TSHRACMSDTDP1
Dipicolinic Acid SCHEMBL6561776 0.80 KDM4E (0.94) KDM4EALOX15TSHRACMSDTDP1
Dipicolinic Acid SCHEMBL2276248 0.80 KDM4E (0.94) KDM4EALOX15TSHRACMSDTDP1
Dipicolinic Acid SCHEMBL11294102 0.80 KDM4E (0.94) KDM4EALOX15TSHRACMSDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP claimed
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 US claimed
US-20230220589-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2023-07-13 US claimed
EP-4127157-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2023-02-08 EP claimed
CN-112194687-B Metal nickel complex with ether bond bridging type bipyridyl carboxylic acid as ligand, and synthesis method and photocatalytic application thereof 云南师范大学 2023-02-03 CN claimed
WO-2022072560-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2022-04-07 WO claimed
WO-2021194908-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2021-09-30 WO claimed
CN-112194687-A Metal nickel complex with ether bond bridging type bipyridyl carboxylic acid as ligand, and synthesis method and photocatalytic application thereof 云南师范大学 2021-01-08 CN claimed
EP-3263566-A1 BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS H. Lundbeck A/S (DK) 2018-01-03 EP claimed
US-20170217950-A1 Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same H. LUNDBECK A/S (DK) 2017-08-03 US claimed
US-9656975-B2 Bicyclo[3.2.1]octyl amide derivatives and uses of same H. LUNDBECK A/S (DK) 2017-05-23 US claimed
EP-2499121-B1 OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. HOFFMANN LA ROCHE (CH) 2015-10-07 EP claimed
US-20150057289-A1 BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2015-02-26 US claimed
US-8921370-B2 Bicyclo[3.2.1]octyl amide derivatives and uses of same H. LUNDBECK A/S (DK) 2014-12-30 US claimed
US-8354441-B2 Oxazoline derivatives HOFFMANN-LA ROCHE INC. (US) 2013-01-15 US claimed
EP-2499121-A1 OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. F. Hoffmann-La Roche AG (CH) 2012-09-19 EP claimed
CN-101343366-A Nano-laminal compound with regular array of pyridine and its derivant, and preparation thereof UNIV SHANGHAI (CN) 2009-01-14 CN claimed
US-20060135367-A1 Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds NEUROGEN CORPORATION (US) 2006-06-22 US claimed
EP-1594848-A1 ARYL ACID PYRIMIDINYL METHYL AMIDES, PYRIDAZINYL METHYL AMIDES AND RELATED COMPOUNDS NEUROGEN CORPORATION (US) 2005-11-16 EP claimed
WO-2004074259-A1 ARYL ACID PYRIMIDINYL METHYL AMIDES, PYRIDAZINYL METHYL AMIDES AND RELATED COMPOUNDS NEUROGEN CORPORATION (US) 2004-09-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217950-A1 Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same SLC10A1, CLIC1, ABCB11 KDM4E 2751/4885ALOX15 1014/4885TSHR 1601/4885
US-20060135367-A1 Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds GABRA2, GABRA1, GABRA5 KDM4E 1365/4885ALOX15 4064/4885TSHR 190/4885
US-20150057289-A1 BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME SLC10A1, CLIC1, ABCB11 KDM4E 3140/4885ALOX15 754/4885TSHR 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.